Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Any info about Iomega (IOM)? -- Ignore unavailable to you. Want to Upgrade?

To: Rocky Reid who wrote (54197)	5/6/1998 10:18:00 AM
From: sheila rothstein	Read Replies (1) \| Respond to of 58324

OT Agree with that move. It's a few years from now until we know whether their 2 blood vessel growth inhibitors will work and as I stated in a previous post to MM that clinical studies will not begin for 1 year. In addition to that I read that other pharm. co's have similar drugs in phase one testing which means that ENMD may Not be the first one to market with this potential anti-cancer drug. The other interesting fact is that these substances, angiostatin and endostatin may not be cures but may be long term inhibitors of the growth of the tumor. (I am not an expert in this field and this is just my interpretation of the news). SR